Search clinical trials for: Inavtivated Quadrivalent Influenza Virus Split Vaccine

Total 546 results

Wuhan Institute of Biological Products Co., Ltd

Active, not recruiting

To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years (QIV)

Influenza

China
Butantan Institute
Fundação Butantan

Recruiting

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Influenza, Human

Brazil
Ab&b Biotechnology Co., Ltd.JS
Henan Center for Disease Control and Prevention

Completed

A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months

Influenza

China
Jiangsu Province Centers for Disease Control and...
Changchun Institute of Biological Products Co., Ltd.

Completed

A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months

Influenza

China
St. Petersburg Research Institute of Vaccines and...

Recruiting

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

Vaccine Reaction | Influenza | Influenza, Human | Influenza Viral Infections

Russian Federation
Sinovac Biotech Co., Ltd
Pontificia Universidad Catolica de Chile; Sinovac Biotech Co., Ltd

Completed

Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Seasonal Influenza

Philippines, Chile
Shanghai Institute Of Biological Products
Shaanxi Provincial Center for Disease Control and Prevention

Recruiting

A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of the Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Belgium, Germany, Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)

Influenza

Austria, Germany, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years

Influenza, Human

China
Hualan Biological Bacterin Co. Ltd.

Completed

Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years

GCP

China
Sinovac Biotech Co., Ltd

Completed

Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated

Seasonal Influenza

China
The Cleveland Clinic

Completed

Influenza Vaccination in Bone Marrow Transplantation

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan

Influenza

Taiwan
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Completed

A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China

Influenza

China
National Institute of Allergy and Infectious Diseases...

Completed

Development of Childhood Anti-Influenza Immunity

Influenza | Influenza Immunisation

United States
Emory University

Recruiting

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

United States
Johns Hopkins Bloomberg School of Public Health
Columbia University; Sanofi Pasteur, a Sanofi Company; Institute of Epidemiology... and other collaborators

Completed

Pregnancy, Arsenic and Immune Response (PAIR)

Influenza | Vaccine Response Impaired | Micronutrient Deficiency | Arsenic--Toxicology | Immunologic Disorders Complicating Pregnancy

Bangladesh
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

Influenza

Australia, Philippines
National Institute of Allergy and Infectious Diseases...

Completed

Age and Response to Flu Vaccines

Influenza | Influenza Immunisation

United States
Hualan Biological Bacterin Co. Ltd.

Completed

Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.

GCP

China
National Institute of Allergy and Infectious Diseases...

Completed

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Influenza | Influenza Immunisation | Avian Influenza

United States
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old

Influenza, Human | Vaccination; Infection | Vaccines

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)

Influenza

Belgium
Ology Bioservices

Completed

Yearly Strain Variation Study, 2010/2011

Influenza | Seasonal Influenza

Austria
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)

Influenza

France
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Influenza | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation

Influenza

Switzerland
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

Influenza

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines

Influenza | Myxovirus Infection | Orthomyxovirus Infections

France
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

Influenza

Russian Federation
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

Influenza

Korea, Republic of
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Influenza

Korea, Republic of
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra

Influenza

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

Influenza | Swine-origin A/H1N1 Influenza

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Seqirus

Completed

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Influenza, Human

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women

Influenza, Human | Vaccination; Infection | Vaccines

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

Influenza

United States
Tel-Aviv Sourasky Medical Center

Unknown

Influenza Vaccination in Fibromyalgia Patients

Fibromyalgia Syndrome

Israel
Duke University
Boston Medical Center; Centers for Disease Control and Prevention; Children's...

Completed

Safety of RIV4 Versus IIV4 in Pregnant Women

Safety | Birth Outcomes | Adverse Event Following Immunisation

United States
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

Influenza, Human

United States

3

Subscribe